Video

Dr. Sotomayor on Personalized Medicine Preventing Cancer

Author(s):

Eduardo Sotomayor, MD

In Partnership With:

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses how personalized medicine may eventually help with preventing cancer.

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses how personalized medicine may eventually help with preventing cancer.

One of the major advances in understanding genetic variations of tumors is next-generation sequencing, Sotomayor explains. This allows practitioners to perform a detailed analysis of tumors or cancer cells, specifically looking at any abnormal genes. This advancement has led researchers to understand many basic causes of cancer.

As a next step, Sotomayor says researchers should now examine lesions that have the potential to become malignant, and work to identify biomarkers and genetic variations in them. This advancement would take place in patients at high risk of developing cancer in the next 1 to 2 years; therefore, an invention could take place with preventative measures and lifestyle changes.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Andrew Kuykendall, MD
October 16th 2023

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

FDA
May 29th 2024

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Vikram M. Narayan, MD, of Emory University Hospital
May 23rd 2024

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

Peter Fasching, MD
May 22nd 2024

Guardant360 CDx Gains European Union Certification for Tumor Profiling in Solid Tumors